print PRINT

SCIENCE > Health

Japan’s supply of remdesivir for COVID-19 may be limited

  • May 2, 2020
  • , Nikkei
  • JMH Summary

Saturday’s Nikkei wrote that it learned from a Health Ministry source that it will probably be difficult for Japan to receive a stable supply of remdesivir to treat all of the coronavirus patients in Japan who need it because although Gilead Sciences is planning to distribute enough for 140,000 patients worldwide, Japan will probably receive only a small portion of the supply. The paper wrote that although the Health Ministry is prepared to approve remdesivir immediately after it is approved overseas, treatment using the drug is unlikely to be covered by the national insurance program until the establishment of a system to provide a sufficient supply for all patients who need it.


  • Ambassador
  • G7 Summit
  • Ukraine